pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
58
stories
3d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
5d
GSK continues to stock up on Wave's RNA drugs with liver-focused program
fiercebiotech
10d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
10d
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
10d
Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
endpoints
10d
ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
endpoints
10d
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
10d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
11d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
12d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
13d
2026 IPO blitz continues with 4 new biotech filings
biospace
14d
ADARx targets $319M IPO as TRexBio, Retension join filing queue
endpoints
19d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
24d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
24d
Novartis drags peers down with triple asset stumble
biospace
24d
Novartis drags peers down with triple asset failure
biospace
25d
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
26d
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
27d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
27d
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
27d
Moonwalk raises $70M to test siRNA treatment for obesity
endpoints
27d
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
29d
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 5, 26
AbbVie-allied ADARx aims for IPO with three drugs in the clinic
endpoints
Sep 3, 26
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
biospace
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Aug 31, 26
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
fiercebiotech
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
fiercebiotech
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
← prev
page 1 of 2
next →
